Interplay between AHR genotypes, lifestyle factors and adjuvant breast cancer treatments significantly impacts clinical outcome in a population-based cohort
BackgroundThe purpose was to evaluate the prognostic impact of aryl hydrocarbon receptor (AHR) genotypes in relation to lifestyle and adjuvant treatments in breast cancer.MethodsAHR genotyping was performed on genomic DNA from 1701 patients included 2002–2016 in Lund, Sweden, and followed for up to 15 years. Eight AHR polymorphisms and eight haplotypes were analysed using survival and interaction
